☆ 4.7 Article

Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Assessment of Safety and Efficacy of Tofacitinib, Stratified by Age, in Patients from the Ulcerative Colitis Clinical Program

Gary R. Lichtenstein et al.

Summary: Age is considered a risk factor for adverse events in the tofacitinib ulcerative colitis clinical program, with older individuals potentially having a higher risk of herpes zoster, malignancies (excluding nonmelanoma skin cancer), and nonmelanoma skin cancer compared to younger patients.

INFLAMMATORY BOWEL DISEASES (2023)

Add to Collection

Article Rheumatology

Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years

Kevin L. Winthrop et al.

Summary: In patients with moderately to severely active rheumatoid arthritis, the safety and tolerability of Filgotinib were good, with a lower incidence of infections in the Filgotinib 200 mg dose group compared to placebo during long-term treatment.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Article Rheumatology

Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials

Kevin L. Winthrop et al.

Summary: In patients with RA, treatment with Upadacitinib (UPA) was associated with higher incidence and event rates of herpes zoster (HZ) compared to treatment with methotrexate (MTX) monotherapy or adalimumab (ADA) + MTX. The risk of HZ was also higher with the 30 mg dose of UPA compared to the 15 mg dose. Patients from Asia and those with a history of HZ may have an increased risk of HZ while receiving UPA.

ANNALS OF THE RHEUMATIC DISEASES (2022)

Add to Collection

Review Gastroenterology & Hepatology

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

Ferdinando D'Amico et al.

Summary: Filgotinib is an effective and safe drug for the treatment of moderate to severe UC, showing similar efficacy but lower risks of thrombosis and herpes zoster infections compared to other JAK inhibitors. However, there may be potential effects on male reproductive organs that require further investigation in human studies.

JOURNAL OF CROHNS & COLITIS (2022)

Add to Collection

Review Gastroenterology & Hepatology

Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis

Carlos Taxonera et al.

Summary: This study confirms the effectiveness of tofacitinib in promoting clinical remission and corticosteroid-free remission in patients with moderate to severely active UC. It also found that tofacitinib has made progress in mucosal healing in UC treatment. Additionally, the safety profile of tofacitinib in UC treatment was found to be acceptable.

INFLAMMATORY BOWEL DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

Steven R. Ytterberg et al.

Summary: In this trial comparing the use of tofacitinib with a TNF inhibitor in a cardiovascular risk-enriched population, the risks of major adverse cardiovascular events (MACE) and cancers were found to be higher with tofacitinib, and it did not meet noninferiority criteria. Several adverse events were more common with tofacitinib.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Review Gastroenterology & Hepatology

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

Juan S. Lasa et al.

Summary: This study compares the efficacy and safety of biologics and small molecule drugs for the treatment of moderate-to-severe ulcerative colitis. The findings show that Upadacitinib performs well in inducing clinical remission, while Vedolizumab performs best in terms of safety.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial

Toshifumi Hibi et al.

Summary: This study evaluated the safety and efficacy of filgotinib in Japanese patients with UC. The results suggest that filgotinib 200 mg may be a viable treatment option for Japanese patients with UC, but caution should be exercised due to the small patient numbers.

INTESTINAL RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies

William J. Sandborn et al.

Summary: The study indicates that ustekinumab exhibits similar safety and efficacy profiles in patients with ulcerative colitis as it does in those with Crohn's disease, with no significant differences compared to placebo.

INFLAMMATORY BOWEL DISEASES (2021)

Add to Collection

Article Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme

Kevin L. Winthrop et al.

Summary: The study reported the infection analysis of patients with ulcerative colitis treated with tofacitinib, revealing that serious infections were more frequent with tofacitinib compared to placebo during induction. In the maintenance and overall cohorts, infection rates were generally low and comparable between treatment groups, with viral infections being rare.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

Dan Turner et al.

Summary: STRIDE-II presents treatment targets for both adult and pediatric IBD, including long-term and short-term goals. These targets cover aspects such as clinical response, endoscopic healing, quality of life, and growth, providing guidance for improving patient outcomes.

GASTROENTEROLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study

Nabeel Khan et al.

Summary: In a retrospective cohort study among elderly patients with inflammatory bowel disease (IBD), the safety profile of VDZ was found to be similar to those taking 5-ASA and favorable compared to those taking chronic steroids in terms of the risk of infection and malignancy.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Rheumatology

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib

Paqui G. Traves et al.

Summary: JAKinibs, including filgotinib, show varying degrees of potency in inhibiting different JAK-dependent pathways in both healthy and RA blood. Filgotinib demonstrates the highest selectivity for JAK1 pathways compared to other JAKinibs, with less inhibition of JAK2-dependent and JAK3-dependent pathways. Ex vivo pharmacodynamic data from phase 1 healthy volunteers confirms the JAK1 selectivity of filgotinib.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease

T. Kucharzik et al.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Gastroenterology & Hepatology

Efficacy and Safety of Tofacitinib Re-treatment for Ulcerative Colitis After Treatment Interruption: Results from the OCTAVE Clinical Trials

Julian Panes et al.

Summary: In patients with ulcerative colitis, re-treatment with tofacitinib can effectively and safely recapture efficacy, regardless of prior treatment failure. Specific efficacy data show that a substantial proportion of patients can achieve clinical response and remission with tofacitinib re-treatment.

JOURNAL OF CROHNS & COLITIS (2021)

Add to Collection

Article Medicine, General & Internal

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Brian G. Feagan et al.

Summary: The study assessed the efficacy and safety of filgotinib in treating ulcerative colitis, with the results showing that 200 mg of filgotinib was more effective than placebo in inducing and maintaining clinical remission.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

The incidence rate of herpes zoster in inflammatory bowel disease A meta-analysis of cohort studies

Shih-Wei Lai et al.

Summary: Patients with inflammatory bowel disease have an increased risk of developing herpes zoster, particularly those with Crohn disease and ulcerative colitis. Vaccination should be considered for patients with inflammatory bowel disease.

MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Risk of common infections in people with inflammatory bowel disease in primary care: a population-based cohort study

Peter M. Irving et al.

Summary: The study evaluated the risk of common infections in individuals with inflammatory bowel disease compared with matched controls in a UK primary care population. It found that people with IBD are more likely to present with a wide range of common infections, with ulcerative colitis and Crohn's disease patients having higher infection risks. Treatment with oral glucocorticoid therapy, immunotherapies, and biologic therapy was associated with increased infection risk in IBD patients.

BMJ OPEN GASTROENTEROLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis

Pablo Olivera et al.

GASTROENTEROLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications

Manasi Agrawal et al.

JOURNAL OF CROHNS & COLITIS (2020)

Add to Collection

Review Medicine, General & Internal

Ulcerative Colitis: Current and Emerging Treatment Strategies

Maia Kayal et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Pharmacology & Pharmacy

Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

Kacey Anderson et al.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2020)

Add to Collection

Article Gastroenterology & Hepatology

Comorbidity, not patient age, is associated with impaired safety outcomes in vedolizumab- and ustekinumab-treated patients with inflammatory bowel disease-a prospective multicentre cohort study

Vera E. R. Asscher et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Article Gastroenterology & Hepatology

Long-term safety of vedolizumab for inflammatory bowel disease

Edward V. Loftus et al.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)

Add to Collection

Review Rheumatology

JAK inhibitors and infections risk: focus on herpes zoster

Flavia Sunzini et al.

THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2020)

Add to Collection

Review Gastroenterology & Hepatology

Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors

Edoardo Troncone et al.

CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

Bruce E. Sands et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Gastroenterology & Hepatology

Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors-Results from the Swiss IBD Cohort Study

Sylvie Scharl et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib

Kevin L. Winthrop et al.

INFLAMMATORY BOWEL DISEASES (2018)

Add to Collection

Article Gastroenterology & Hepatology

The safety of vedolizumab for ulcerative colitis and Crohn's disease

Jean-Frederic Colombel et al.

GUT (2017)

Add to Collection

Article Immunology

Herpes Zoster in the Older Adult

Amrita R. John et al.

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2017)

Add to Collection

Article Medicine, General & Internal

Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies

Siew C. Ng et al.

LANCET (2017)

Add to Collection

Review Medicine, General & Internal

Ulcerative colitis

Ryan Ungaro et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Geriatrics & Gerontology

Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients

Nabeel Khan et al.

DRUGS & AGING (2017)

Add to Collection

Article Pharmacology & Pharmacy

Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects

Mathurin Flamant et al.

DRUGS (2017)

Add to Collection

Article Gastroenterology & Hepatology

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2, and 3

Jean-Frederic Colombel et al.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

William J. Sandborn et al.

GASTROENTEROLOGY (2014)

Add to Collection

Review Medicine, General & Internal

Systematic review of incidence and complications of herpes zoster: towards a global perspective

Kosuke Kawai et al.

BMJ OPEN (2014)

Add to Collection

Article Medicine, General & Internal

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Brian G. Feagan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

Walter Reinisch et al.

GUT (2011)

Add to Collection

Article Geriatrics & Gerontology

The Burden of Cardiovascular Disease in the Elderly: Morbidity, Mortality, and Costs

Ali Yazdanyar et al.

CLINICS IN GERIATRIC MEDICINE (2009)

Add to Collection

Article Medicine, General & Internal

Infliximab for induction and maintenance therapy for ulcerative colitis

P Rutgeerts et al.

NEW ENGLAND JOURNAL OF MEDICINE (2005)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study

G Järnerot et al.

GASTROENTEROLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.